Literature DB >> 3520916

Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension.

G J Slotman, K W Burchard, J J Williams, A D'Arezzo, S A Yellin.   

Abstract

Activated complement, thromboxane A2, prostacyclin, and activated granulocytes have been implicated in hemodynamic dysfunction after trauma, in sepsis, and in hypovolemic and septic shock. This study evaluated the interaction of plasma concentrations of complement components C3a and C5a, thromboxane B2 (TxB), prostaglandin 6-keto-F1 alpha (PGI), and granulocyte aggregation in clinical sepsis and hypotension. Forty-eight critically ill patients were followed clinically for as long as 10 days. Plasma C3a, C5a, TxB, and PGI were measured daily by the radioimmunoassay method. Granulocyte aggregation, the percentage of maximum aggregation of zymosan-activated plasma standard curves, was performed with patient plasma and normal human leukocytes. Patients were studied in four groups: group I, nonseptic, normotensive; group II, hypovolemic shock, group III, normotensive severe sepsis; and group IV, septic shock. Plasma from 12 normal adults was the control value. PGI, TxB, C3a, C5a, and granulocyte aggregation in patients were greater than that in the control subjects. Granulocyte aggregation was increased in groups III and IV versus groups I and II. C3a was increased in group IV versus groups II and III. C5a and TxB did not vary between groups. PGI was greatly increased in group IV compared with groups I through III. C3a and C5a decreased in nonsurvivors. PaO2/FiO2 ratios correlated directly with PGI and inversely with C3a and TxB/PGI. Plasma PGI and C3a are increased in septic shock. C3a and TxB/PGI imbalances are involved in hypovolemic and septic shock.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3520916

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  11 in total

Review 1.  [Causes and therapy of organ failure: mediators, their role and therapeutic implications as exemplified by the infected patient].

Authors:  H Neuhof
Journal:  Langenbecks Arch Chir       Date:  1987

Review 2.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

3.  Complement anaphylatoxin C3a and C5a formation in premature children with respiratory distress.

Authors:  A Enskog; A Bengtsson; J P Bengtson; M Heideman; S Andreasson; L Larsson
Journal:  Eur J Pediatr       Date:  1996-01       Impact factor: 3.183

4.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

5.  Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis.

Authors:  J A Green; G M Smith; R Buchta; R Lee; K Y Ho; I A Rajkovic; K F Scott
Journal:  Inflammation       Date:  1991-10       Impact factor: 4.092

6.  Prostacyclin biosynthesis and reduced 5-HT uptake after complement-induced endothelial injury in the dog isolated lung.

Authors:  H Bult; J J Heiremans; A G Herman; C M Malcorps; F A Peeters
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

7.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors:  S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

8.  Effects of C1 esterase inhibitor administration on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation during experimental endotoxemia.

Authors:  Christian Lehmann; Jürgen Birnbaum; Carsten Lührs; Oskar Rückbeil; Claudia Spies; Sabine Ziemer; Matthias Gründling; Dragan Pavlovic; Taras Usichenko; Michael Wendt; Wolfgang J Kox
Journal:  Intensive Care Med       Date:  2003-10-29       Impact factor: 17.440

Review 9.  The role of complement system in septic shock.

Authors:  Jean Charchaflieh; Jiandong Wei; Georges Labaze; Yunfang Joan Hou; Benjamin Babarsh; Helen Stutz; Haekyung Lee; Samrat Worah; Ming Zhang
Journal:  Clin Dev Immunol       Date:  2012-09-23

10.  The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.

Authors:  J W Baars; C E Hack; J Wagstaff; A J Eerenberg-Belmer; G J Wolbink; L G Thijs; R J Strack van Schijndel; H L van der Vall; H M Pinedo
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.